怡达股份子公司拟收购万淇生物科技(泰州)85%股权

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan [1] Group 1: Acquisition Details - The acquisition involves the purchase of 85% equity in Wanqi Biotechnology (Taizhou) Co., Ltd. by the company's subsidiary, Taixing Yida Chemical Co., Ltd. [1] - The total investment for this acquisition is 24.565 million yuan [1] Group 2: Strategic Objectives - The acquisition is part of the company's strategy to promote high-end and refined product development [1] - The company intends to leverage Wanqi's years of production experience and sales channel advantages to advance the construction of epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - This move is expected to optimize the company's capacity layout, enrich its product line, and enhance production capabilities to effectively meet downstream customer demands [1]